StreetInsider.com News Articles

Form 4 Immunovant, Inc. For: May 28 Filed by: Fromkin Andrew J.

Fri, 29 May 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260529/26575004.html

Form 4 Immunovant, Inc. For: May 28 Filed by: Fromkin Andrew J.

Fri, 29 May 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260529/26575004.html

Form 144 Immunovant, Inc. Filed by: Fromkin Andrew J.

Thu, 28 May 2026 16:13:00 -0400

si-local-file:///var/storage/secattach/20260528/26567426.html

Form 144 Immunovant, Inc. Filed by: Fromkin Andrew J.

Thu, 28 May 2026 16:13:00 -0400

si-local-file:///var/storage/secattach/20260528/26567426.html

Immunovant (IMVT) PT Raised to $62 at Guggenheim

Tue, 26 May 2026 06:38:18 -0400

Guggenheim analyst Yatin Suneja raised the price target on Immunovant (NASDAQ: IMVT) to $62.00 (from $44.00) while maintaining a Buy rating.

Form 4 Immunovant, Inc. For: May 20 Filed by: Gloria Melanie

Fri, 22 May 2026 16:03:00 -0400

si-local-file:///var/storage/secattach/20260522/26541426.html

Form 4 Immunovant, Inc. For: May 20 Filed by: Gloria Melanie

Fri, 22 May 2026 16:03:00 -0400

si-local-file:///var/storage/secattach/20260522/26541426.html

Immunovant (IMVT) PT Raised to $30 at Truist Securities

Fri, 22 May 2026 07:05:35 -0400

Truist Securities analyst Danielle Brill raised the price target on Immunovant (NASDAQ: IMVT) to $30.00 (from $23.00) while maintaining a Hold rating.

Immunovant (IMVT) PT Raised to $35 at Bernstein SocGen Group

Thu, 21 May 2026 08:55:55 -0400

Bernstein SocGen Group analyst William Pickering raised the price target on Immunovant (NASDAQ: IMVT) to $35.00 (from $28.00) while maintaining a Market Perform rating.

Immunovant (IMVT) PT Raised to $40 at H.C. Wainwright

Thu, 21 May 2026 06:36:41 -0400

(Updated - May 21, 2026 6:36 AM EDT)

H.C. Wainwright analyst Douglas Tsao raised the price target on Immunovant (NASDAQ: IMVT) to $40.00 (from $35.00) while maintaining a Buy rating.

The analyst commented: "The company reported compelling response rates of 72.7% ACR20, 54.5% ACR50, and 35.8% ACR70 at week 16 in the open-label period of the Phase 2 study from 165 highly refractory RA patients. Efficacy was preserved in the JAK/TNF refractory subgroup (n=107), with 72% ACR20, 53.3% ACR50, and 37.4% ACR70, indicating prior exposure to multiple advanced therapies did not meaningfully diminish treatment benefit, suggesting FcRn works via a distinct mechanism

Immunovant (IMVT) PT Raised to $40 at H.C. Wainwright

Thu, 21 May 2026 06:36:41 -0400

(Updated - May 21, 2026 6:36 AM EDT)

H.C. Wainwright analyst Douglas Tsao raised the price target on Immunovant (NASDAQ: IMVT) to $40.00 (from $35.00) while maintaining a Buy rating.

Immunovant (IMVT) PT Raised to $43 at BofA Securities

Thu, 21 May 2026 05:19:40 -0400

BofA Securities analyst Jason Gerberry raised the price target on Immunovant (NASDAQ: IMVT) to $43.00 (from $32.00) while maintaining a Buy rating.

The analyst comments "We raise our Immunovant (IMVT) PO to $43/sh (from $32) on a higher peak sales outlook for IMVT-1402, now $6.8bn (vs. $5.5bn prior), driven by greater contribution from GD & D2T RA—both large ‘white-space’ TAMs. Our revision incorporates DT2A derisking from Period 1 data (reported yesterday) and potential upside from upcoming pivotal readouts. We are most bullish on GD (50% of valuation) given strong prior data and unmet need. While CLE/SjD are sizable markets, we assign

Immunovant (IMVT) PT Raised to $43 at BofA Securities

Thu, 21 May 2026 05:19:40 -0400

BofA Securities analyst Jason Gerberry raised the price target on Immunovant (NASDAQ: IMVT) to $43.00 (from $32.00) while maintaining a Buy rating.

Form 4 Immunovant, Inc. For: May 20 Filed by: Pande Atul

Wed, 20 May 2026 21:22:00 -0400

si-local-file:///var/storage/secattach/20260520/26530094.html

Form 4 Immunovant, Inc. For: May 20 Filed by: Pande Atul

Wed, 20 May 2026 21:22:00 -0400

si-local-file:///var/storage/secattach/20260520/26530094.html

Form 144 Immunovant, Inc. Filed by: Pande Atul

Wed, 20 May 2026 16:38:00 -0400

si-local-file:///var/storage/secattach/20260520/26529036.html

Form 144 Immunovant, Inc. Filed by: Pande Atul

Wed, 20 May 2026 16:38:00 -0400

si-local-file:///var/storage/secattach/20260520/26529036.html

Stifel Reiterates Buy Rating on Immunovant (IMVT) following Q4 results and IMVT-1402 data

Wed, 20 May 2026 11:50:09 -0400

Stifel analyst Alex Thompson reiterated a Buy rating and $49.00 price target on Immunovant (NASDAQ: IMVT) following Q4 results and trial results from IMVT-1402 in rheumatoid arthritis,

The analyst commented, "We are reiterating our Buy rating on IMVT following their F4Q26 report, which featured topline data from the open label Part 1 portion of their IMVT-1402 D2T RA study. Notably, while enrichment for patients with inadequate response to 2+ therapies and ACPA+ makes cross trial comparison challenging, absolute response rates of 70%+ on ACR20 look better than nipocalimab PoC data. Looking ahead, management plans to share additional updates from the program

Form 10-K Immunovant, Inc. For: Mar 31

Wed, 20 May 2026 07:28:00 -0400

si-local-file:///var/storage/secattach/20260520/26524794.html

Form 10-K Immunovant, Inc. For: Mar 31

Wed, 20 May 2026 07:28:00 -0400

si-local-file:///var/storage/secattach/20260520/26524794.html

Form 8-K Immunovant, Inc. For: May 20

Wed, 20 May 2026 07:14:00 -0400

si-local-file:///var/storage/secattach/20260520/26524755.html

Form 8-K Immunovant, Inc. For: May 20

Wed, 20 May 2026 07:14:00 -0400

si-local-file:///var/storage/secattach/20260520/26524755.html

Immunovant, Inc. (IMVT) Misses Q4 EPS by 13c

Wed, 20 May 2026 07:04:12 -0400

Immunovant, Inc. (NASDAQ: IMVT) reported Q4 EPS of ($0.73), $0.13 worse than the analyst estimate of ($0.60).

For earnings history and earnings-related data on Immunovant, Inc. (IMVT) click here.

Immunovant reports mixed trial results for IMVT-1402 in rheumatoid arthritis

Wed, 20 May 2026 07:03:07 -0400

Immunovant Inc. (NASDAQ: IMVT) reported preliminary results from its IMVT-1402 trial in difficult-to-treat rheumatoid arthritis, showing response rates of 72.7% ACR20, 54.5% ACR50 and 35.8% ACR70 at Week 16. The company also announced it discontinued development of batoclimab after two Phase 3 studies in thyroid eye disease failed to meet primary endpoints.

The IMVT-1402 trial enrolled 170 participants with rheumatoid arthritis who had failed two or more prior advanced therapies. Of 165 evaluable patients, 86.7% had failed two prior mechanisms of advanced therapies, with a mean diagnosis time of 12.8 years. The study measured improvement in joint counts and clinical parameters

Immunovant reports mixed trial results for IMVT-1402 in rheumatoid arthritis

Wed, 20 May 2026 07:03:07 -0400